Blood Thinners Reduce Need for Cardiovascular and Respiratory Support in Certain COVID-19 Patients

Sep 1, 2021 | News

Dr. Steve Wisniewski’s ACTIV-4A team just had 2 papers published in the New England Journal of Medicine. The UPMC news release is below along with the links to the two papers which just appeared.

 

Blood Thinners Reduce Need for Cardiovascular and Respiratory Support in Certain COVID-19 Patients

Giving moderately ill, hospitalized COVID-19 patients a full dose of a blood thinner improved their chances of leaving the hospital without needing mechanical ventilation. But this strategy did not yield the same results for COVID-19 patients who were critically ill, who needed intensive care-level support at the time of enrollment.

These are the findings of two new studies published in The New England Journal of Medicine (NEJM). The studies incorporated data from three platform trials as part of a global collaboration to identify possible treatments during the height of the pandemic. The trials are “Accelerating COVID-19 Therapeutic Interventions and Vaccines-4” (ACTIV4a): A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults with COVID-19, “Antithrombotic Therapy to Ameliorate Complications of COVID-19” (ATTACC), and “Randomized, Embedded, Multi-factorial Adaptive Platform Trial for Community-Acquired Pneumonia” (REMAP-CAP) Therapeutic Anticoagulation.

Read Full Article ›


 

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19 ›
The REMAP-CAP, ACTIV-4a, and ATTACC Investigators

Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 ›
The ATTACC, ACTIV-4a, and REMAP-CAP Investigators